Undisputed market leader with 80%+ market share, Q3'23 showed non-conclusive evidence of peers encroaching on Medistim's dominance.
slow and steady wins the race :)
Aren't you concerned that the organic growth was negative and only FX gains leading to the +6.5% in Q3? Furthermore, the number of CBAG surgeries are slightly declining due to the increased use of stents.
Great breakdown of the business model and your approach to valuation.
What do you think about the poor Q4 numbers? -17% (currency-adjusted) is quite tough. Do you have a view how GLP-1 may be impacting their business?
slow and steady wins the race :)
Aren't you concerned that the organic growth was negative and only FX gains leading to the +6.5% in Q3? Furthermore, the number of CBAG surgeries are slightly declining due to the increased use of stents.
Great breakdown of the business model and your approach to valuation.
What do you think about the poor Q4 numbers? -17% (currency-adjusted) is quite tough. Do you have a view how GLP-1 may be impacting their business?